Cargando…

Effects of brimonidine tartrate 0.2 and 0.15% ophthalmic solution on the static and dynamic pupil characteristics

AIMS: To investigate the differences between 0.2 and 0.15% brimonidine tartrate eye drops for anti-mydriatic effects and the optical quality under different light conditions. METHODS: This prospective study involved 80 consecutive high myopia patients undergoing implantation of a V4c ICL. The patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jing, Zhang, Xiaodi, Zhong, Mei, Bai, Yanhui, Liu, Wentao, Hu, Jinge, Wang, Weiqun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225522/ https://www.ncbi.nlm.nih.gov/pubmed/37256086 http://dx.doi.org/10.3389/fmed.2023.1160414

Ejemplares similares

Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex
por: Kato, C. O. Sayaka, et al.
Publicado: (2018)

Effect of over-the-counter brimonidine tartrate 0.025% ophthalmic solution on pupil size in healthy adults
por: Nejad, Mitra, et al.
Publicado: (2021)

Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study
por: Orii, Yusuke, et al.
Publicado: (2022)

Comparative Analysis of Pupil Diameters in Light and Dark Conditions After Instillation of 0.15% Brimonidine Drops in Eyes With and Without Pseudoexfoliation Syndrome
por: Cate, Sercan, et al.
Publicado: (2020)

Effect of Topical Brimonidine 0.15% on Conjunctival Injection after Strabismus Surgery in Children
por: Kim, Dong Hyun, et al.
Publicado: (2021)

The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations
por: Alonso, Ruiz Simonato, et al.
Publicado: (2020)

Ocular Distribution of Brimonidine and Brinzolamide after Topical Instillation of a 0.1% Brimonidine Tartrate and 1% Brinzolamide Fixed-Combination Ophthalmic Suspension: An Interventional Study
por: Orii, Yusuke, et al.
Publicado: (2023)

An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
por: Fung, Derrick S, et al.
Publicado: (2014)

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily
por: Moisseiev, Elad, et al.
Publicado: (2013)

A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma
por: Gómez-Aguayo, Francisco, et al.
Publicado: (2018)

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial
por: McLaurin, Eugene, et al.
Publicado: (2018)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Durán, Leopoldo Martín, et al.
Publicado: (2012)

Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes
por: Colin, Joseph
Publicado: (2007)

Fluorimetric Quantification of Brimonidine Tartrate in Eye Drops
por: Sunitha, G., et al.
Publicado: (2013)

The role of brimonidine tartrate gel in the treatment of rosacea
por: Jackson, J Mark, et al.
Publicado: (2015)

Bilateral Lipid Keratopathy in the Setting of Brimonidine Tartrate Use
por: Moshirfar, Majid, et al.
Publicado: (2023)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
por: Lee, Anne J, et al.
Publicado: (2008)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe, Craig F, et al.
Publicado: (2012)

Use of brimonidine tartrate to resolve telangiectatic matting: case report
por: de Mello, Brenno Augusto Seabra, et al.
Publicado: (2020)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients
por: Tsumura, Toyoaki, et al.
Publicado: (2014)

Prolonged central nervous system and respiratory depression in preterm neonates after exposure to brimonidine tartrate and timolol maleate ophthalmic drops
por: Azarcon, Corrina P., et al.
Publicado: (2020)

Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications
por: Chou, Timothy Y, et al.
Publicado: (2014)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]
Publicado: (2015)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]
Publicado: (2015)

Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate
por: Kasuya, Yuka, et al.
Publicado: (2020)

Evaluation of Nd(0.8−x)Sr(0.2)Ca(x)CoO(3−δ)(x = 0, 0.05, 0.1, 0.15, 0.2) as a cathode material for intermediate-temperature solid oxide fuel cells
por: Du, Xu, et al.
Publicado: (2022)

Preparation and Evaluation of Nano-vesicles of Brimonidine Tartrate as an Ocular Drug Delivery System
por: Prabhu, P, et al.
Publicado: (2010)

Augmented in vitro and in vivo Profiles of Brimonidine Tartrate Using Gelatinized-Core Liposomes
por: Abdel Azim, Engy A, et al.
Publicado: (2022)

Preparation and Characterization of Ion-Sensitive Brimonidine Tartrate In Situ Gel for Ocular Delivery
por: Xu, Haonan, et al.
Publicado: (2023)

Improving Output Power of InGaN Laser Diode Using Asymmetric In(0.15)Ga(0.85)N/In(0.02)Ga(0.98)N Multiple Quantum Wells
por: Wang, Wenjie, et al.
Publicado: (2019)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Reproducible long-term cycling data of Al(2)O(3) coated LiNi(0.70)Co(0.15)Mn(0.15)O(2) cathodes for lithium-ion batteries
por: Negi, Rajendra S., et al.
Publicado: (2022)

Preparation, Characterization, and Photocatalytic Performance of Ag/BiOBr(0.85)I(0.15) Nanocomposites
por: Hu, Xiaobin, et al.
Publicado: (2022)

Patient-controlled epidural analgesia after Caesarean section: levobupivacaine 0.15% versus ropivacaine 0.15% alone or combined with fentanyl 2 µg/ml: a comparative study
por: Matsota, Paraskevi, et al.
Publicado: (2011)

Formulation and evaluation of stimuli-sensitive hydrogels of timolol maleate and brimonidine tartrate for the treatment of glaucoma
por: Dubey, Akhilesh, et al.
Publicado: (2014)

Cu-doped Nd(0.6)Sr(0.4)Co(1−x)Cu(x)O(3−δ) (x = 0, 0.05, 0.1, 0.15, 0.2) as the cathode for intermediate-temperature solid oxide fuel cells
por: Du, Xu, et al.
Publicado: (2023)

Anomalous excess noise behavior in thick Al(0.85)Ga(0.15)As(0.56)Sb(0.44) avalanche photodiodes
por: Lewis, Harry I. J., et al.
Publicado: (2023)

Review on Multicatalytic Behavior of Ba(0.85)Ca(0.15)Ti(0.9)Zr(0.1)O(3) Ceramic
por: Gaur, Akshay, et al.
Publicado: (2023)

Investigation of Proton Induced Radiation Effects in 0.15 µm Antifuse FPGA
por: Placinta, Vlad-Mihai
Publicado: (2018)

Exploring multiple effects of Zn(0.15)Mg(0.85)O nanoparticles on Bacillus subtilis and macrophages
por: Auger, Sandrine, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vv0n3lk8b05prud1k6rur4q7t5